RxDoctor Payments Data

Vincent Lem, MD

Pulmonary Disease · Kansas City, MONPI 1366444143

Payments from drug & device makers

$167in general payments, 2019–2025

Across 7 payments — averaging $23.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$73
  • AstraZeneca$28
  • Regeneron$26
  • CSL Behring$20
  • Insmed, Inc.$17
  • United Therapeutics Corporation$3

What the payments were for

  • Food & beverage$11669%
  • Education$5131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$167 in reported general payments places this provider in the 20th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$178,371
Medicare patients
564
Services billed
2,418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate20$246,992
Prolastin CAlpha-1-Proteinase Inhibitor26$234,605
Trelegy ElliptaFluticasone/Umeclidin/Vilanter244$229,257
NucalaMepolizumab34$158,820
TezspireTezepelumab-Ekko27$118,621
Breztri AerosphereBudesonide/Glycopyr/Formoterol115$96,371
Fasenra PenBenralizumab17$95,566
Pirfenidone26$83,139
Dupixent PenDupilumab17$64,644
Breo ElliptaFluticasone/Vilanterol103$58,263
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr119$56,413
Stiolto RespimatTiotropium Br/Olodaterol Hcl73$49,805
Spiriva RespimatTiotropium Bromide64$46,458
SymbicortBudesonide/Formoterol Fumarate96$30,906
EliquisApixaban31$25,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaTezspire, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$28$266,798270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →